Sarang Mangalmurti, MD
Cardiovascular Disease · Bryn Mawr, PANPI 1790984003
Payments from drug & device makers
Across 1,022 payments — averaging $1284.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$833K
- Philips North America LLC$201K
- Contego Medical, Inc$81K
- Cardiovascular Systems Inc.$52K
- Cagent Vascular Inc$49K
- Abbott$43K
- plus $54K from 47 others
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vesalio, Inc.$10K
What the payments were for
- Consulting fees$358,51349%
- Speaking & faculty fees$273,73838%
- Travel & lodging$24,5723%
- Food & beverage$36,8205%
- Education$34,0115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$226,572
- Vascular Lithotripsy$151,211
- Diamondback Coronary$61,067
- (9520) IGT Devices Undivided$59,241
- Serrantor$44,502
- Phoenix Catheter System$32,000
- FARXIGA$28,272
- IGT D Peripheral$25,200
- Spectranetics Undiv$22,800
- IVUS Systems$16,000
- Coronary Orbital Atherectomy System$13,425
- Tack Endovascular System$9,643
- Omnilink Elite vascular stent system$9,600
- IN.PACT Admiral$5,000
- US Und$4,800
- Serranator$4,800
- Diamondback Peripheral$4,607
- Peripheral Orbital Atherectomy System$3,062
- (R11) US EQ Undivided$2,400
- (9715) Azurion 5 M20$1,169
How this compares
$1,312,565 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $101,669 |
| XareltoRivaroxaban | 54 | $53,884 |
| Repatha SureclickEvolocumab | 24 | $22,391 |
| EntrestoSacubitril/Valsartan | 20 | $20,081 |
| BrilintaTicagrelor | 18 | $16,799 |
| ClopidogrelClopidogrel Bisulfate | 216 | $3,869 |
| Metoprolol Succinate | 142 | $2,540 |
| Atorvastatin Calcium | 159 | $2,112 |
| Rosuvastatin Calcium | 55 | $1,175 |
| Losartan Potassium | 44 | $983 |
| Nitroglycerin | 17 | $961 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 23 | $859 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 17 | $646 |
| Amlodipine Besylate | 72 | $583 |
| Ezetimibe | 31 | $542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $780 | $101,66991 claims |
| Johnson & JohnsonXarelto | $555 | $53,88454 claims |
| NovartisEntresto | $555 | $20,08120 claims |
| AstraZenecaBrilinta | $29,023 | $16,79918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Bryn Mawr
- Sheetal ChandhokBryn Mawr$848K
- Joel RaichlenBryn Mawr$250K
- Danielle DuffyPhiladelphia$29.5M
- Venkatesh NadarCamp Hill$18.3M
- Hemal GadaWormleysburg$6.7M
- Brian DrachmanPhiladelphia$3.8M
- William BachinskyMechanicsburg$2.3M
- Bonnie KyPhiladelphia$1.9M
- Benjamin KalsmithPgh$1.7M
- Marielle Scherrer CrosbiePhiladelphia$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.